A First-in Human, Phase I Trial to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LY4336619, an Alkaline Phosphatase Placental-Like 2 (ALPPL2) T- Cell Engager Bispecific Antibody, in Adult Participants With Advanced Solid Tumors

Study Identifier:
J7L-MC-JUEA
CT.gov Identifier:
EudraCT Identifier:
EU Trial (CTIS) Number:
Study Contact Information:
Will Be Recruiting

Considering participating in a START clinical trial?

Study Summary

The main purpose of this study is to evaluate how safe and effective LY4336619 is in adults with advanced cancer. Some participants will receive LY4336619 alone, and some will receive it with another cancer medicine. Participants will be in the study for up to 2 years, depending on how they tolerate and respond to treatment.

Clinical Study Information for Healthcare Providers

By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

Study Locations

Location
Investigator
Status
Condition(s) Treated at Site
Location
START New York (Long Island)
Lake Success, NY, United States, 11042
Investigator
Geraldine O'Sullivan Coyne
Status
Will Be Recruiting
Condition(s) Treated at Site
Non-Small Cell Lung Cancer
Ovarian
Gastric
Solid Tumor
Endometrial
Testicular
Location
START Mountain Region
West Valley City, UT, United States, 84119
Investigator
William McKean
Status
Will Be Recruiting
Condition(s) Treated at Site
Non-Small Cell Lung Cancer
Ovarian
Gastric
Solid Tumor
Endometrial
Testicular